San Diego Business Journal

SD HEALTHCARE

Recent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...

Foundations Recovery Network Opens San Diego Operation

Nashville-based Foundations Recovery Network, a behavioral health company and integrated treatment provider, has opened a location in San Diego.

Kura Oncology Raises $60 Million in Private Stock Offering

Kura Oncology Inc., a precision medicine company pursuing treatments for solid tumors and blood cancers, announced Thursday that it has raised $60 million in a private stock offering.

Independa Closes $6 Million Series B Funding Round

Independa, an integrated community engagement and remote care technologies company, announced it has closed its Series B funding round, raising $6 million.

Mirati Therapeutics Reports Q4 Net Loss of $10.4 Million

San Diego-based Mirati Therapeutics Inc., a company developing medicines for targeted oncology, announced its fourth quarter financial results on March 11, reporting a net loss of $10.4 million. In the same quarter of 2013, the company reported a net loss of $11.2 million.

Accriva Diagnostics Raises $15 Million in Equity Financing

Accriva Diagnostics Holdings Inc., a hospital-based cardiovascular diagnostic company, has raised $15.5 million in equity financing according to a recent regulatory filing.

Price of Acadia Shares Soar on Speculation of Possible Sale

Shares of San Diego-based Acadia Pharmaceuticals Inc. rose to its highest price ever after the company canceled two investor meetings, sparking speculation that a deal to buy the drugmaker could be in the works, according to Bloomburg Business.

Mountain Health Names Blain to CMO Post

Mountain Health, a private, nonprofit regional community health center providing health care, health education and community services, named Arthur Blain, M.D., as its new chief medical officer.

Zogenix Sells Zohydro ER Business to New Jersey-Based Pernix

San Diego-based Zogenix Inc. announced that it has agreed to sell its Zohydro ER business to New Jersey-based Pernix Therapeutic Holdings Inc. for $100 million, plus regulatory and sales milestones up to $283.5 million.

Zafgen Reports Positive Clinical Results With Obesity-Related Drug

Zafgen Inc., a biopharmaceutical company developing treatments for obesity and metabolic disorders, announced positive clinical data from a recently completed Phase 2 trial of its obesity-related drug beloranib.

Epic Sciences Announces Collaboration With Consortium

Epic Sciences Inc., a San Diego-based diagnostic company, announced a collaboration with The Prostate Cancer Clinical Trials Consortium in which Epic’s circulating tumor cell technology will be applied in multiple studies.

Regen Files Patent Application for a Cancer Drug

Regen BioPharma Inc. announced that it has filed a patent application for a therapy for the treatment of myelodysplastic syndrome.

Former Biotech Exec Now Curing Sales and Marketing Woes

Richard Hollis’ name has long been associated with biotechnology. But the 2008 recession and an unpleasant end to his last enterprise, Hollis-Eden Pharmaceuticals, got him thinking about new directions.

TearLab Announces $35M Term Loan Agreement

San Diego-based TearLab Corp. has entered into a term loan agreement with health-care-focused investment firm CRG for up to $35 million in borrowing capacity, TearLab said.

Clinical Trials Will Put Ebola Drug’s Effectiveness to the Test

Mapp Biopharmaceutical, the local Ebola drugmaker that’s brewing antibody cocktails in tobacco plants, took another step toward combating the deadly virus last month when the U.S. and Liberian governments joined forces to begin testing the effectiveness of Mapp’s experimental drug in humans.

Tease photo

Health Systems Busy Building Up in County

MEDICINE: Seismic Retrofits, More Services Drive Activity

Health systems in San Diego County are facing a deadline to retrofit hospital buildings — or build new ones — to meet the state’s rigorous seismic safety standards by 2030.